NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Gevo, Inc. (NASDAQ:GEVO), OSI Systems, Inc. (NASDAQ:OSIS), Senseonics Holdings, Inc. (NYSE:SENS), and Donnelley Financial Solutions Inc. (NYSE:DFIN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
ADRO DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADRO
PGNX DOWNLOAD: http://Fundamental-Markets.com/register/?so=PGNX
GEVO DOWNLOAD: http://Fundamental-Markets.com/register/?so=GEVO
OSIS DOWNLOAD: http://Fundamental-Markets.com/register/?so=OSIS
SENS DOWNLOAD: http://Fundamental-Markets.com/register/?so=SENS
DFIN DOWNLOAD: http://Fundamental-Markets.com/register/?so=DFIN
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Gevo, Inc. (NASDAQ:GEVO), OSI Systems, Inc. (NASDAQ:OSIS), Senseonics Holdings, Inc. (NYSE:SENS), and Donnelley Financial Solutions Inc. (NYSE:DFIN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 3rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ADURO BIOTECH, INC. (ADRO) REPORT OVERVIEW
Aduro Biotech's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Aduro Biotech reported revenue of $3.79MM vs $3.79MM (unchanged) and basic earnings per share -$0.33 vs -$0.54. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Aduro Biotech reported revenue of $50.68MM vs $72.98MM (down 30.55%) and basic earnings per share -$1.40 vs -$0.88. Aduro Biotech is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is -$1.28 and is expected to report on March 7th, 2018.
To read the full Aduro Biotech, Inc. (ADRO) report, download it here: http://Fundamental-Markets.com/register/?so=ADRO
-----------------------------------------
PROGENICS PHARMACEUTICALS INC. (PGNX) REPORT OVERVIEW
Progenics Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Progenics Pharmaceuticals reported revenue of $2.70MM vs $53.85MM (down 94.99%) and basic earnings per share -$0.22 vs $0.52. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Progenics Pharmaceuticals reported revenue of $69.43MM vs $8.68MM (up 700.24%) and basic earnings per share $0.15 vs -$0.56. Progenics Pharmaceuticals is expected to report earnings on March 8th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.63 and is expected to report on March 8th, 2018.
To read the full Progenics Pharmaceuticals Inc. (PGNX) report, download it here: http://Fundamental-Markets.com/register/?so=PGNX
-----------------------------------------
GEVO, INC. (GEVO) REPORT OVERVIEW
Gevo's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Gevo reported revenue of $7.70MM vs $6.94MM (up 10.87%) and basic earnings per share -$0.25 vs -$2.04. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Gevo reported revenue of $27.21MM vs $30.14MM (down 9.70%) and basic earnings per share -$9.68 vs -$51.61. Gevo is expected to report earnings on April 4th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$1.14. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on April 4th, 2018.
To read the full Gevo, Inc. (GEVO) report, download it here: http://Fundamental-Markets.com/register/?so=GEVO
-----------------------------------------
OSI SYSTEMS, INC. (OSIS) REPORT OVERVIEW
OSI's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, OSI reported revenue of $257.13MM vs $220.86MM (up 16.43%) and basic earnings per share $0.54 vs $0.04 (up 1,250.00%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, OSI reported revenue of $960.95MM vs $829.66MM (up 15.82%) and basic earnings per share $1.12 vs $1.35 (down 17.04%). OSI is expected to report earnings on January 25th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.68. The estimated EPS forecast for the next fiscal year is $3.75 and is expected to report on August 23rd, 2018.
To read the full OSI Systems, Inc. (OSIS) report, download it here: http://Fundamental-Markets.com/register/?so=OSIS
-----------------------------------------
SENSEONICS HOLDINGS, INC. (SENS) REPORT OVERVIEW
Senseonics' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Senseonics reported revenue of $2.10MM vs $0.04MM (up 5,567.57%) and basic earnings per share -$0.13 vs -$0.12. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Senseonics reported revenue of $0.33MM vs $0.04MM (up 773.68%) and basic earnings per share -$0.49 vs -$4.32. Senseonics is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.57 and is expected to report on February 22nd, 2018.
To read the full Senseonics Holdings, Inc. (SENS) report, download it here: http://Fundamental-Markets.com/register/?so=SENS
-----------------------------------------
DONNELLEY FINANCIAL SOLUTIONS INC. (DFIN) REPORT OVERVIEW
Donnelley Financial Solutions' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Donnelley Financial Solutions reported revenue of $222.60MM vs $224.40MM (down 0.80%) and basic earnings per share $0.16 vs $0.31 (down 48.39%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Donnelley Financial Solutions reported revenue of $983.50MM vs $1,049.50MM (down 6.29%) and basic earnings per share $1.81 vs $3.22 (down 43.79%). Donnelley Financial Solutions is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.10. The estimated EPS forecast for the next fiscal year is $1.46 and is expected to report on February 27th, 2018.
To read the full Donnelley Financial Solutions Inc. (DFIN) report, download it here: http://Fundamental-Markets.com/register/?so=DFIN
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.